Exploring how Oncotype DX test results interact with CHEK2, ATM, and PALB2 germline pathogenic variants in breast cancer treatment decisions.
Explore how Oncotype DX genomic testing is transforming breast cancer treatment decisions across diverse populations in North Carolina through precision medicine.